A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic …
Objective Gastric cancer is a major gastrointestinal malignancy for which targeted therapies
are emerging as treatment options. This study sought to identify the most prevalent …
are emerging as treatment options. This study sought to identify the most prevalent …
[HTML][HTML] Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
The fibroblast growth factor receptor (FGFR) cascade plays crucial roles in tumor cell
proliferation, angiogenesis, migration and survival. Accumulating evidence suggests that in …
proliferation, angiogenesis, migration and survival. Accumulating evidence suggests that in …
Phase I dose-escalation study of JNJ-42756493, an oral pan–fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors
J Tabernero, R Bahleda, R Dienstmann… - Journal of clinical …, 2015 - ascopubs.org
Purpose JNJ-42756493 is an orally administered pan-fibroblast growth factor receptor
(FGFR) tyrosine kinase inhibitor. This first-in-human study evaluates the safety …
(FGFR) tyrosine kinase inhibitor. This first-in-human study evaluates the safety …
Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives
The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling pathway
plays a fundamental role in many physiologic processes, including embryogenesis, adult …
plays a fundamental role in many physiologic processes, including embryogenesis, adult …
Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer
AN Brooks, E Kilgour, PD Smith - Clinical cancer research, 2012 - AACR
The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling axis plays
an important role in normal organ, vascular, and skeletal development. Deregulation of …
an important role in normal organ, vascular, and skeletal development. Deregulation of …
Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities
P Perez-Moreno, E Brambilla, R Thomas, JC Soria - Clinical cancer research, 2012 - AACR
Lung cancer is the leading cause of cancer-related deaths worldwide. Next to
adenocarcinoma, squamous cell carcinoma (SCC) of the lung is the most frequent histologic …
adenocarcinoma, squamous cell carcinoma (SCC) of the lung is the most frequent histologic …
Discovery of pemigatinib: a potent and selective fibroblast growth factor receptor (FGFR) inhibitor
L Wu, C Zhang, C He, D Qian, L Lu, Y Sun… - Journal of Medicinal …, 2021 - ACS Publications
Aberrant activation of FGFR has been linked to the pathogenesis of many tumor types.
Selective inhibition of FGFR has emerged as a promising approach for cancer treatment …
Selective inhibition of FGFR has emerged as a promising approach for cancer treatment …
Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer
MT Herrera-Abreu, A Pearson, J Campbell… - Cancer discovery, 2013 - AACR
Activation of fibroblast growth factor receptors (FGFR) is a common oncogenic event. Little is
known about the determinants of sensitivity to FGFR inhibition and how these may vary …
known about the determinants of sensitivity to FGFR inhibition and how these may vary …
Emerging therapeutic targets in metastatic progression: a focus on breast cancer
Z Li, Y Kang - Pharmacology & therapeutics, 2016 - Elsevier
Metastasis is the underlying cause of death for the majority of breast cancer patients.
Despite significant advances in recent years in basic research and clinical development …
Despite significant advances in recent years in basic research and clinical development …
FGFR as potential target in the treatment of squamous non small cell lung cancer
M Tiseo, F Gelsomino, R Alfieri, A Cavazzoni… - Cancer treatment …, 2015 - Elsevier
To date therapeutic options for squamous cell lung cancer patients remain scarce because
no druggable targets have been identified so far. Aberrant signaling by FGFs (fibroblast …
no druggable targets have been identified so far. Aberrant signaling by FGFs (fibroblast …